Vedanta Biosciences Awarded $5.8 Million CARB-X Grant to Accelerate Development of VE707 for Multi-Drug Resistant Infections
05 Diciembre 2019 - 1:00AM
Business Wire
Vedanta Biosciences eligible for an additional
$3.5 million upon completion of certain milestones
Program addresses significant unmet therapeutic
need for major hospital-acquired infections caused by multi-drug
resistant organisms
Vedanta Biosciences, a clinical-stage biopharmaceutical company
developing a new category of therapies for immune-mediated diseases
based on defined bacterial consortia, today announced that it has
been awarded a second research grant from CARB-X (Combating
Antibiotic Resistant Bacteria Biopharmaceutical Accelerator), a
global non-profit partnership dedicated to accelerating early
development in antibacterial R&D to address the rising global
threat of drug-resistant bacteria, of $5.8 million. In addition to
the initial grant, Vedanta Biosciences is eligible for $3.5 million
in further funding upon completion of specific milestones.
The funding will be directed towards the development of VE707,
Vedanta’s preclinical human microbiome-derived discovery program
designed to restore a healthy microbiota as well as prevent
infection and colonization recurrence of several multi-drug
resistant organisms (MDRO) that are responsible for hundreds of
thousands of infections in high-risk patients in the United States
and Europe each year.
“The addition of Vedanta’s VE707 program to the CARB-X portfolio
expands the rich diversity of our pipeline and reflects a novel
approach against drug-resistant infections,” said Kevin Outterson,
executive director of CARB-X. “Innovations such as VE707, if
successful and approved for use in patients, could offer physicians
broader treatment options that would strengthen a patient’s ability
to fight serious infections and limit the spread of drug-resistant
bacteria.”
VE707 is designed to prevent MDRO infections that can result in
life-threatening treatment delays and death. These infections
result in approximately $2 billion of additional healthcare costs
relating to patient isolation practices alone.
“We are very pleased to partner with CARB-X for a second time
and look forward to working with the CARB-X team to develop an
alternative to antibiotics to help address the burden of MDRO
infections,” said Bernat Olle, PhD, chief executive officer of
Vedanta Biosciences. “If we could get rid of intestinal carriage of
these MDROs in high-risk patients, we could not only prevent
infections, but also curb the transmission of these organisms and
enable physicians to avoid using antibiotics that select for
ever-more resistant bacterial strains.”
Vedanta Biosciences received its first grant from CARB-X for
$5.4 million in 2017 to support clinical testing of Vedanta’s oral
product candidate, VE303, for the potential treatment of recurrent
Clostridioides difficile infection (rCDI).
About VE707 VE707 is Vedanta’s preclinical discovery
program for the prevention of infection and colonization recurrence
of several MDROs. VE707 is designed to be administered orally and
consists of a defined consortium of commensal bacteria. It is
produced from pure, clonal bacterial cell banks, which yield a
product of uniform composition and free of any pathogenic strains,
bypassing the need to rely on fecal donor material with
inconsistent composition. VE707 is designed to decolonize
gut-dwelling multi-drug resistant organisms in patients at
high-risk for developing infections. Specifically, VE707 is being
developed to eliminate intestinal carriage of carbapenem-resistant
Enterobacteriaceae (CRE), extended-spectrum beta lactamase
producers (ESBL), and vancomycin-resistant Enterococci (VRE) to
restore a healthy microbiota as well as prevent infection and
colonization recurrence. CRE, ESBL, and VRE infections are some of
the most common hospital-acquired infections and are estimated to
affect over 500,000 intensive care unit, dialysis, solid organ
transplant, and hematopoietic stem cell transplant patients each
year in the U.S. and Europe. Infections with these organisms can
result in life-threatening treatment delays or death and result in
approximately $2 billion healthcare-associated costs due to patient
isolation practices alone.
About CARB-X Combating Antibiotic-Resistant Bacteria
Biopharmaceutical Accelerator (CARB-X) is a global non-profit
partnership dedicated to accelerating early development
antibacterial R&D to address the rising global threat of
drug-resistant bacteria. CARB-X is led by Boston University and
funding is provided by the Biomedical Advanced Research and
Development Authority (BARDA), part of the Office of the Assistant
Secretary for Preparedness and Response (ASPR) in the U.S.
Department of Health and Human Services, the Wellcome Trust, a
global charity based in the U.K. working to improve health
globally, Germany’s Federal Ministry of Education and Research
(BMBF), the Bill & Melinda Gates Foundation, and with in-kind
support from National Institute of Allergy and Infectious Diseases
(NIAID), part of the U.S. National Institutes of Health (NIH). A
non-profit partnership, CARB-X is investing up to $500 million from
2016-2021 to support innovative antibiotics and other therapeutics,
vaccines, and rapid diagnostics. CARB-X supports the world’s
largest and most innovative pipeline of preclinical products
against drug-resistant infections. CARB-X is headquartered at
Boston University School of Law. https://carb-x.org/. Follow us on
Twitter @CARB_X.
About Vedanta Biosciences Vedanta Biosciences is a
clinical-stage microbiome leader developing a new category of
therapies for immune-mediated diseases based on rationally-defined
consortia of human microbiome-derived non-pathogenic bacteria.
Vedanta’s proprietary capabilities include what is believed to be
the largest collection of human-gut associated bacteria, assays and
bioinformatics techniques for consortia design and optimization,
vast datasets from human interventional studies and facilities for
cGMP-compliant manufacturing of rationally-defined bacterial
consortia in powder form.
Vedanta Biosciences' pioneering work, in collaboration with its
scientific co-founders, has led to the identification of human
commensal bacteria that induce a range of immune responses –
including induction of regulatory T cells, CD8+ T cells, and Th17
cells, among others. These advances have been published in leading
peer-reviewed journals, including Science (multiple), Nature (2013,
2019), Cell, and Nature Immunology. Vedanta Biosciences has
harnessed these biological insights and its capabilities to
generate a pipeline of investigational live biotherapeutic products
(LBPs) in infectious disease, autoimmune disease, allergy, and
immuno-oncology. This pipeline includes three clinical-stage
product candidates currently being evaluated for the treatment of
recurrent C. difficile infection and inflammatory bowel disease (in
collaboration with Janssen Biotech, Inc.), and food allergy, as
well as a fourth product candidate expected to enter the clinic in
2019 in patients with advanced or metastatic cancers (in
combination with Bristol-Myers Squibb’s checkpoint inhibitor
OPDIVO®).
Vedanta’s IP portfolio contains over 30 issued patents with
coverage through at least 2031. Vedanta Biosciences was founded by
PureTech Health (LSE: PRTC). Its scientific co-founders are
world-renowned experts in immunology and microbiology who have
pioneered the fields of innate immunity, Th17 and regulatory T cell
biology.
Forward Looking Statement This press release contains
statements that are or may be forward-looking statements, including
statements that relate to the company's future prospects,
developments, and strategies. The forward-looking statements are
based on current expectations and are subject to known and unknown
risks and uncertainties that could cause actual results,
performance and achievements to differ materially from current
expectations, including, but not limited to, those risks and
uncertainties described in the risk factors included in the
regulatory filings for PureTech Health plc. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law and regulatory requirements, neither the company
nor any other party intends to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191204005928/en/
Investors Allison Mead Talbot +1 617 651 3156
amt@puretechhealth.com U.S. media Tom Donovan +1 857 559
3397 tom@tenbridgecommunications.com
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Puretech Health (LSE:PRTC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024